KDR and prostate carcinoma: For instances, SU5416, the VEGFR2 inhibitor eliminated melanoma microvasculature [26]; imatinib mesylate, the PDGFR inhibitor blocked the angiogenesis in prostate cancer bone metastases [27]; Ki8751, the VEGFR inhibitor reversed MDR1 up-regulation and endothelial cells chemo-resistance [28].